Literature DB >> 12721908

Accelerated rubella control and congenital rubella syndrome prevention strengthen measles eradication: the Costa Rican experience.

Ana Morice1, Xinia Carvajal, Mario León, Vicenta Machado, Xiomara Badilla, Susan Reef, Fabio Lievano, Ariel Depetris, Carlos Castillo-Solórzano.   

Abstract

In 2000, Costa Rica set a goal for accelerated rubella control and congenital rubella syndrome (CRS) prevention in conjunction with its established measles eradication goal. To achieve this goal, a National Plan of Action for the integration of a measles-rubella (MR) vaccination strategy was implemented. The components of the national plan included conducting a national vaccination campaign with a single dose of MR vaccine for men and women aged 15-39 years, establishing routine postpartum MR vaccination of all previously unvaccinated women, maintaining high coverage among children with two doses of measles-mumps-rubella vaccine, strengthening the integrated measles and rubella surveillance system, and developing a CRS surveillance system. This report summarizes the results of a successful adult campaign. Targeting MR vaccination appropriately and using the opportunity to strengthen surveillance for rash illness has benefits beyond accelerated rubella control and CRS prevention, including strengthening of the measles eradication program.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12721908     DOI: 10.1086/368053

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Structured models of infectious disease: inference with discrete data.

Authors:  C J E Metcalf; J Lessler; P Klepac; A Morice; B T Grenfell; O N Bjørnstad
Journal:  Theor Popul Biol       Date:  2011-12-09       Impact factor: 1.570

2.  Determinants of adults' intention to vaccinate against pandemic swine flu.

Authors:  Lynn B Myers; Robin Goodwin
Journal:  BMC Public Health       Date:  2011-01-06       Impact factor: 3.295

3.  [The role of long-acting release (LAR) depot octreotide as adjuvant management of short bowel disease].

Authors:  Efraín Gómez-Herrera; Oscar Alejandro Farías-Llamas; José Luis Gutiérrez-de la Rosa; José Manuel Hermosillo-Sandoval
Journal:  Cir Cir       Date:  2004 Sep-Oct       Impact factor: 0.361

4.  Residual susceptibility to measles among young adults in Victoria, Australia following a national targeted measles-mumps-rubella vaccination campaign.

Authors:  Heath A Kelly; Heather F Gidding; Theo Karapanagiotidis; Jennie A Leydon; Michaela A Riddell
Journal:  BMC Public Health       Date:  2007-06-08       Impact factor: 3.295

5.  Introduction of rubella-containing-vaccine to Madagascar: implications for roll-out and local elimination.

Authors:  Amy Wesolowski; Keitly Mensah; Cara E Brook; Miora Andrianjafimasy; Amy Winter; Caroline O Buckee; Richter Razafindratsimandresy; Andrew J Tatem; Jean-Michel Heraud; C Jessica E Metcalf
Journal:  J R Soc Interface       Date:  2016-04       Impact factor: 4.118

6.  Rubella vaccination in India: identifying broad consequences of vaccine introduction and key knowledge gaps.

Authors:  A K Winter; S Pramanik; J Lessler; M Ferrari; B T Grenfell; C J E Metcalf
Journal:  Epidemiol Infect       Date:  2017-12-04       Impact factor: 2.451

Review 7.  Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications.

Authors:  F T Cutts; E Dansereau; M J Ferrari; M Hanson; K A McCarthy; C J E Metcalf; S Takahashi; A J Tatem; N Thakkar; S Truelove; E Utazi; A Wesolowski; A K Winter
Journal:  Vaccine       Date:  2019-11-29       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.